Evidence map›Paper›PMID 26180776›Full record

ArticleThe journal of prevention of Alzheimer's disease2015

Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial.

E L Abner, R J Kryscio, A M Caban-Holt, F A Schmitt

2 registry-linked trialsAbstract read
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00040378 completednot on this map

Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

TypeobservationalSponsorFrederick SchmittRan2002 to 2016Enrolled4,246ConditionsAlzheimer DiseaseArmsalphatocopherol, Selenium, Placebo replacement for vitamin E, Placebo replacement for Selenium
NCT07284316 phase2 / phase3active not recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance: A Randomized Clinical Trial

TypeinterventionalSponsorInstituto Mexicano del Seguro SocialRan2025 to 2027Enrolled100ConditionsCognitive Decline, Subjective Cognitive Impairment, Insulin ResistanceArmsTurmeric extract, Control: Placebo. 500mg gelatin in capsules 2 times a day
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Statins for the prevention of dementia.The Cochrane database of systematic reviews · 2016
    Pooled it
  3. Trial
  4. Review
  5. Article
  6. Comparing Short Cognitive Screening Instruments in an Outreach Memory Clinic in Primary Care.International journal of environmental research and public health · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

E L AbnerSanders-Brown Center on Aging, University of Kentucky ; Department of Epidemiology, University of Kentucky.
R J KryscioSanders-Brown Center on Aging, University of Kentucky ; Department of Biostatistics, University of Kentucky ; Department of Statistics, University of Kentucky.
A M Caban-HoltSanders-Brown Center on Aging, University of Kentucky ; Department of Behavioral Science, University of Kentucky.
F A SchmittSanders-Brown Center on Aging, University of Kentucky ; Department of Behavioral Science, University of Kentucky ; Department of Neurology, University of Kentucky.

Funding

SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
University of Kentucky Alzheimer's Disease Core Center - Biomarker CoreP30AG028383 · NIA · UNIVERSITY OF KENTUCKY · PI GOLD, BRIAN TIMOTHY, VAN ELDIK, LINDA J · 2006 to 2020
$23.3M
Prevention of Alzheimer's Diseae by Vitamin E and SeleniumR01AG019241 · NIA · UNIVERSITY OF KENTUCKY · PI SCHMITT, FREDERICK · 2001 to 2012
$12.1M
Role of impaired cognitive states & risk factors in conversion to mixed dementiasR01AG038651 · NIA · UNIVERSITY OF KENTUCKY · PI ABNER, ERIN, KRYSCIO, RICHARD J. · 2011 to 2023
$6.1M
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2M
NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA182883NIA NIH HHS P30 AG028383NIA NIH HHS R01 AG019241NIA NIH HHS R01 AG038651
6 · The paper itself

Abstract

backgroundSubjective memory complaints reflect patient-identified deficits in memory and have been linked to increased risk of future dementia in nondemented (including cognitively intact) older adults.

objectivesTo assess the risk of incident dementia during follow-up for participants in the Prevention of Alzheimer's Disease with Vitamin E and Selenium (PREADVISE) study who reported memory complaints at baseline.

designDouble-blind, placebo controlled 2×2 randomized controlled trial that transformed into an observational cohort following discontinuation of supplementation in the SELECT parent trial.

settingPREADVISE participants were assessed at 130 local clinical study sites in the United States, Canada, and Puerto Rico during the controlled trial phase and were later followed by telephone from a centralized location during the observational phase.

participantsPREADVISE enrolled a total of 7,547 nondemented men over the age of 60; 4,271 consented to participation in the observational study. MEASUREMENTS: Participants were interviewed at baseline for memory complaints. The Memory Impairment Screen (MIS) was administered to each participant at the annual memory screening. Participants who failed the MIS also received a more detailed neurocognitive assessment: an expanded Consortium to Establish a Registry in Alzheimer's Disease (CERADe) neuropsychological battery was used during the RCT, and the modified Telephone Interview for Cognitive Status (TICS-m) was used during the observational study. Participants who failed the second screen were asked to have a memory work-up with a local physician and to share their medical records with PREADVISE. Subgroups of men who did not fail the MIS were also asked to complete the CERADe battery and TICS-m for validation purposes. Additional measures collected include self-reported medical history, medication use, and the AD8 Dementia Screening Test.

resultsAfter controlling for important risk factors for dementia, Cox proportional hazards regression revealed that men who reported memory changes at baseline had an 80% increase in the hazard of incident dementia compared to men who reported no SMC. Men who reported memory problems at baseline had almost a 6-fold increase in the hazard of incident dementia compared to men who reported no memory complaint.

conclusionsMemory complaints in nondemented older men predicted future dementia. Men who reported that the changes in their memory were a problem were especially at risk, and the presence of common comorbidities like diabetes, sleep apnea, and history of head injury further exacerbated this risk.

Indexed as

dementialongitudinal cohortsubjective memory complaints

Identifiers

PMID26180776
PMCPMC4500536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.